Apple Lands a Buy Call as a 200,000-Person Health-AI Study Gets Underway
Published on 11/16/2026 at 14:11 | Editorial boerse-global.deChina Renaissance moved Apple to "Buy" from "Hold" on Wednesday, with analyst Jack Zhou setting a $425 price target. The upgrade rests on potential growth catalysts from the anticipated foldable iPhone. Shares were up 0.7% on the day, trading at €323.50 in pre-market action, a gain of 0.077%.
The bullish note landed alongside a business outlook in which Apple flagged rising memory costs and softer-than-expected growth in its services division.
Fourth-Quarter Figures
For the fourth fiscal quarter of 2026, reported on November 2, Apple posted revenue of $114.48 billion — up 12% year over year. Diluted earnings per share came in at $2.10.
Should investors sell immediately? Or is it worth buying Apple?
Looking to the December quarter, the company guided to a gross margin of 45% to 46% and projected services revenue growth of 8% to 9%.
A Research Push Into Health AI
Separately, Apple teamed up with OpenEvidence yesterday to launch the Apple Health AI Usage Study, a US research effort open to as many as 200,000 eligible participants. The project examines how people interact with conversational artificial intelligence on health topics.
Three areas form the core of the investigation: how far users trust such applications, how well they comprehend the responses, and how they engage with the offerings day to day. The study also assesses the quality of the answers themselves. Apple said the study data will not be used to train AI models.
Ad
Apple Stock: New Analysis - 16 November
Fresh Apple information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
